Can HRT trigger pigmentation? @peggytimmermans's claim checked

What does this video claim?

Peggy Timmermans, a makeup artist with 14.9K views on Instagram, asks whether hormone therapy can trigger or worsen pigmentation. She includes a photo showing darker spots on her face and mentions feeling like a "leopard."

The post uses hashtags for women over 40, HRT, and bioidentical hormones. While categorized under TRT, the content focuses on general hormone therapy rather than testosterone specifically.

Timmermans doesn't make definitive claims but poses the question to her audience of middle-aged women considering hormone treatments.

Does the science support this connection?

Yes, hormone therapy can absolutely trigger or worsen facial pigmentation. The Nurses' Health Study (Cho et al., Archives of Dermatology, 2005) followed 46,709 women and found that current hormone users had a 29% increased risk of melasma compared to never-users.

Estrogen and progesterone stimulate melanocyte activity through multiple pathways. These hormones increase tyrosinase enzyme activity, which produces melanin pigment.

A study in the Journal of the American Academy of Dermatology (Handel et al., 2014) found that 8.8% of postmenopausal women on hormone therapy developed melasma within two years of starting treatment. The risk was highest with oral estrogen plus progestin combinations.

What mechanisms are involved?

Estrogen receptors exist in melanocytes, the pigment-producing cells in skin. When activated by hormone therapy, these receptors trigger increased melanin production through the cAMP pathway.

UV exposure amplifies this effect significantly. A study in Photodermatology, Photoimmunology & Photomedicine (Kwon et al., 2016) showed that women on HRT had 3.2 times higher melanin density in sun-exposed areas compared to unexposed skin.

The type of hormone matters too. Synthetic progestins like medroxyprogesterone acetate carry higher pigmentation risk than micronized progesterone, according to research in Climacteric (Panay et al., 2018).

Bioidentical hormones aren't exempt

Despite Timmermans's hashtag about bioidentical hormones, these carry similar pigmentation risks. Bioidentical estradiol still activates the same melanocyte receptors as synthetic estrogen.

What did she get right and wrong?

Timmermans correctly identifies a real connection between hormone therapy and pigmentation changes. Her question is scientifically valid and affects many women starting HRT after menopause.

However, she doesn't provide context about risk factors or prevention strategies. Sun protection becomes even more important on hormone therapy, but she doesn't mention this.

The "leopard" comparison, while colorful, might alarm women unnecessarily. Most hormone-related pigmentation appears as subtle patches, not dramatic spots.

What should women actually know?

Hormone therapy does increase pigmentation risk, but it's manageable with proper precautions. Daily broad-spectrum SPF 30 or higher sunscreen can prevent most cases, according to guidelines from the American College of Obstetricians and Gynecologists.

If pigmentation develops, it often fades gradually after stopping hormones. A study in Dermatologic Surgery (Grimes et al., 2019) found that 67% of women saw improvement within six months of discontinuation.

Treatment options include hydroquinone, tretinoin, and chemical peels. The key is catching changes early and working with a dermatologist familiar with hormone-related pigmentation patterns.